NFKB1 and malignant glioma: However, it is worth to mention that a variability of the NF-κB response to CK2 inhibitors was noticed [83], and a delayed activation of NF-κB has been suggested as correlated with resistance to CK2 inhibitors in malignant gliomas [83].